63 results on '"A. Druzd-Sitek"'
Search Results
2. Mass Spectrometry-Based Assessment of M-protein in Peripheral Blood During Maintenance Therapy in Multiple Myeloma
3. Therapeutic adherence and assessment of satisfaction patients with multiple myeloma treated with immunomodulatory drugs in a “real-world” study: Experiences of the Polish Myeloma Group
4. Identification of novel genetic loci for risk of multiple myeloma by functional annotation
5. Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial
6. Outpatient treatment with 2 cycles of Bendamustine, Gemcitabine and Dexamethasone is Effective and Safe in r/r Hodgkin Lymphoma—Polish Lymphoma Research Group Study
7. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization
8. SARS-CoV-2 infection in patients with multiple myeloma: survey in 23 centers across Europe and USA
9. Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine ( R‐MIV ) in patients with primary CNS lymphoma including recent COVID ‐19 pandemic experience
10. A Stepwise Screening Protocol for Multiple Myeloma
11. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial
12. A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk
13. OAB-010: Atlas: a phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma
14. High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up
15. S175: ATLAS: A PHASE 3 RANDOMIZED TRIAL OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE ALONE AFTER STEM-CELL TRANSPLANT FOR MULTIPLE MYELOMA
16. Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma
17. Antimicrobial prophylaxis in adults and children undergoing hematopoietic cell transplantation: 2021 Polish recommendations
18. A polygenic risk score for multiple myeloma risk prediction
19. Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group
20. Safety and Early Efficacy of Obinutuzumab in Combination with Chemotherapy in Treatment Naive Patients with Follicular Lymphoma - Report of Polish Lymphoma Research Group (PLRG)
21. Protective environment in hematopoietic cell transplantation centers: results of a survey of the Polish Federation of Bone Marrow Transplant Centers
22. Genetically determined telomere length and multiple myeloma risk and outcome
23. Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients
24. Common gene variants within 3′‐untranslated regions as modulators of multiple myeloma risk and survival
25. Antimicrobial prophylaxis in patients after hematopoietic cell transplantation: results of a survey of the Polish Federation of Bone Marrow Transplant Centers
26. Primary refractory multiple myeloma: a real-world experience with 85 cases
27. Clinicopathological characteristics and outcome of plasmablastic lymphoma patients: A single-center retrospective analysis.
28. Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium
29. Tumor and Cerebrospinal Fluid microRNAs in Primary Central Nervous System Lymphomas
30. Wyzwania wczesnej diagnostyki szpiczaka plazmocytowego – algorytm diagnostyczny
31. High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group
32. OFATUMUMAB WITH IVAC FOR DLBCL PATIENTS WHO FAILED R-CHOP AND WERE NOT CANDIDATES FOR HIGH-DOSE THERAPY AND ASCT - PHASE 2 TRIAL OF THE POLISH LYMPHOMA RESEARCH GROUP (PLRG-8)
33. Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study
34. Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2018/2019
35. Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients
36. 11 reasons for ESA application in hematooncology
37. Praktyka kliniczna oceny minimalnej choroby resztkowej u chorych na szpiczaka plazmocytowego w Polsce: badanie ankietowe Polskiego Konsorcjum Szpiczakowego
38. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients
39. Real-life experience with bortezomib-based regimens in elderly comorbid patients with newly diagnosed multiple myeloma – Polish retrospective multicenter analysis
40. HIGH EFFICACY AND SAFETY OF VTD AS AN INDUCTION PROTOCOL IN NEWLY DIAGNOSED MM PATIENTS ELIGIBLE FOR HDT/AUTOSCT - A REPORT OF POLISH MULTIPLE MYELOMA STUDY GROUP
41. The outcome of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements or NOS compared to DLBCL patients from a single institution.
42. Możliwości leczenia indukcyjnego chorych na szpiczaka plazmocytowego kwalifikujących się do chemioterapii wysokodawkowanej wspomaganej autologiczną transplantacją komórek krwiotwórczych a aktualne zalecenia Polskiej Grupy Szpiczakowej
43. Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2017
44. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group
45. Identification of miRSNPs associated with the risk of multiple myeloma
46. Outcome of primary gastrointestinal compared to nodal diffuse large B cell lymphoma in a series of consecutive patients treated at a single institution
47. Central nervous system involvement by multiple myeloma: A multi‐institutional retrospective study of 172 patients in daily clinical practice
48. Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2016
49. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients
50. Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients—Report of the Polish Myeloma Group
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.